Streetbeat News

Regulatory

BA

LUV

UAL

Southwest Airlines expects fewer Boeing jet deliveries this year, impacting its growth. Initially planning for 85 Boeing MAX jets, now only about 20 are expected due to Boeing's production cuts and regulatory issues. This reduction affects Southwest's operational targets and financial outlook, with similar challenges faced by United Airlines.

Portfolio Pulse from Shivani Kumaresan

April 12, 2024 | 1:31 pm

BTCUSD

ETHUSD

Hong Kong is set to approve spot Bitcoin and Ether ETFs, potentially this week, positioning itself as a major player in the cryptocurrency ETF market. This move, reported by Bloomberg citing sources, involves Harvest Fund Management and a partnership between Bosera Asset Management and HashKey Capital as frontrunners for approval. The approval marks a shift from futures-based to spot crypto ETFs in Hong Kong, amid efforts to become a leading digital asset hub. This follows the successful launch of spot Bitcoin ETFs in the US, which have significantly boosted the cryptocurrency market.

Portfolio Pulse from Murtuza Merchant

April 12, 2024 | 12:58 pm

AMD

AVGO

INTC

MRVL

NVDA

QCOM

Despite US-China tensions, China remains a crucial market for U.S. semiconductor firms like Nvidia, Intel, Broadcom, Qualcomm, and Marvell Technology. These companies continue to report greater revenues from China than the U.S., even amid stringent export controls targeting AI-related chips. U.S. firms have adapted by developing modified AI chips for China to comply with regulations, while maintaining a technological lead. The Semiconductor Industry Association has called for a de-escalation of tensions, as China moves towards semiconductor self-reliance and the U.S. plans further restrictions on Chinese chipmaking facilities.

Portfolio Pulse from Benzinga Neuro

April 12, 2024 | 12:58 pm

ABT

CMI

NFE

NIO

PLTR

PNC

Jim Cramer recommended buying shares of Cummins Inc. (CMI), New Fortress Energy Inc. (NFE), Palantir Technologies Inc. (PLTR), The PNC Financial Services Group, Inc. (PNC), and Abbott Laboratories (ABT), citing various reasons for each. He advised selling shares of NIO Inc. (NIO). Notable updates include New Fortress Energy's upsizing and pricing of senior secured notes, Cummins' coverage initiation by Truist Securities, Palantir's partnership with Oracle, PNC's price target update by Jefferies, and FDA approval of Abbott Laboratories' TriClip system. NIO filed its annual report.

Portfolio Pulse from Avi Kapoor

April 12, 2024 | 12:43 pm

RWLK

ReWalk Robotics has announced that the Centers for Medicare & Medicaid Services have revised the DMEPOS Fee Schedule for April 2024, setting a final lump-sum Medicare purchase fee for personal exoskeletons. The fee range is set from $109,238 to $81,929, with a standardized rate of $91,032 for each state.

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 12:32 pm

GLD

Gold prices are on the rise due to ongoing uncertainty in the Middle East, purchases by China's central bank, and speculation around US Federal Reserve policies.

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 12:21 pm

JPM

JPMorgan Chase's CFO commented on the current quarter's performance in investment banking as 'nice' but expressed caution regarding future activity due to regulatory headwinds in mergers and acquisitions (M&A).

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 12:10 pm

EIS

INDA

USO

The India Foreign Ministry has issued an advisory against travel to Iran and Israel for Indians until further notice, as reported by Reuters citing an official statement.

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 12:07 pm

EKSO

Ekso Bionics has received the final payment determination for Medicare reimbursement from the Centers for Medicare & Medicaid Services for its Ekso Indego Personal product. The final payment level has been set at $91,031.93.

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 12:04 pm

LLY

NVO

The Pharmacovigilance Risk Assessment Committee (PRAC) has found no evidence linking GLP-1 diabetes medications, including dulaglutide, exenatide, liraglutide, lixisenatide, and semaglutide, to suicidal or self-injurious behavior. This conclusion comes after reviewing case reports, additional data from marketing authorization holders, and recent studies. Medications such as Ozempic, Rybelsus, Wegovy, Victoza, Saxenda, Xultophy, Byetta, Bydureon, Lyxumia, Suliqua, and Trulicity are cleared of these concerns. Marketing authorization holders will continue to monitor and report on safety.

Portfolio Pulse from Benzinga Newsdesk

April 12, 2024 | 12:02 pm